睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06684600,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC), and local recurrence or distant metastasis;

    入选标准第 2 条

  3. Patients undergoing first-line systemic chemotherapy progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.

    入选标准第 3 条

    At least one measurable/evaluable lesion by RECIST v1.1. And the measurable lesions should not have received local treatment such as radiotherapy (The lesion located in the previous radiotherapy area, if confirmed to progress, and meets the RECIST 1.1 standard, can also be used as a target lesion).

    入选标准第 4 条

    Female subjects of childbearing potential must undergo a blood pregnancy test within 72 hours prior to the first administration of the drug and the result must be negative. They must not be breastfeeding and must agree to use effective contraception during the trial period and for at least 7 months after the last use of Dalpiciclib or at least 8 weeks after the last use of Pyrotinib, whichever is longer. Male subjects with partners of childbearing potential must be surgically sterilized or agree to use effective contraception during the trial period and for at least 7 months after the last use of Dalpiciclib or at least 8 weeks after the last use of Pyrotinib, whichever is longer. Sperm donation is not allowed during the study period.

    入选标准第 17 条

    Prior radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy within 4 weeks of enrollment (eligible for enrollment if the last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment); prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment.

    排除标准第 4 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

    入选标准第 6 条

  5. ANC≥1.5×109/L

    入选标准第 10 条

    TBIL≤1.5 × ULN,ALT and AST ≤ 2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN

    入选标准第 14 条

    plasma Cr ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min.

    入选标准第 15 条

    APTT and INR ≤1.5 × ULN

    入选标准第 16 条

  6. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.

    排除标准第 9 条

    Active infections, including but not limited to tuberculosis. 14. History of immunodeficiency, including positive HIV testing, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.

    排除标准第 14 条

  7. Pregnant or lactating women, or women of childbearing potential with a positive baseline pregnancy test.

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06684600,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 18\~75 years, both men and women.;
  2. Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC), and local recurrence or distant metastasis;
  3. Patients undergoing first-line systemic chemotherapy progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.
  4. At least one measurable/evaluable lesion by RECIST v1.1. And the measurable lesions should not have received local treatment such as radiotherapy (The lesion located in the previous radiotherapy area, if confirmed to progress, and meets the RECIST 1.1 standard, can also be used as a target lesion).
  5. Tissue samples shall be provided for biomarker analysis, preferably newly acquired tissues, and patients who are unable to provide newly acquired tissues may provide 5-8 pieces of 5um thick paraffin sections that are archived and preserved.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Capable of swallowing tablets normally.
  8. Life expectancy of ≥ 12 weeks.
  9. The main organs function normally, that is, the following criteria are met:
  10. ANC≥1.5×109/L
  11. PLT≥90×109/L;
  12. HB≥90g/L;
  13. ALB≥28g/L;
  14. TBIL≤1.5 × ULN,ALT and AST ≤ 2.5ULN; if there is liver metastasis, ALT and AST ≤ 5ULN
  15. plasma Cr ≤ 1.5ULN or creatinine clearance (CCr) ≥ 60ml / min.
  16. APTT and INR ≤1.5 × ULN
  17. Female subjects of childbearing potential must undergo a blood pregnancy test within 72 hours prior to the first administration of the drug and the result must be negative. They must not be breastfeeding and must agree to use effective contraception during the trial period and for at least 7 months after the last use of Dalpiciclib or at least 8 weeks after the last use of Pyrotinib, whichever is longer. Male subjects with partners of childbearing potential must be surgically sterilized or agree to use effective contraception during the trial period and for at least 7 months after the last use of Dalpiciclib or at least 8 weeks after the last use of Pyrotinib, whichever is longer. Sperm donation is not allowed during the study period.
  18. Subjects voluntarily joined the study, signed informed consent, and were well-adhered to follow-u.

排除标准:Exclusion Criteria:

  1. Presence of clinically significant symptoms and uncontrollable third-space fluid accumulations, such as large pleural effusions or ascites, that cannot be managed through drainage or other methods.
  2. Chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction, among other factors that may affect medication intake and absorption.
  3. Prolonged corticosteroid therapy exceeding 30 days or requiring long-term corticosteroid use.
  4. Prior radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy within 4 weeks of enrollment (eligible for enrollment if the last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment); prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment.
  5. Unresolved adverse events related to prior treatments to less than grade 2 (excluding alopecia, asthenia, and adverse events deemed by the investigator not to affect eligibility).
  6. Participation in another clinical trial of a new drug within 4 weeks, unless the trial is observational (non-interventional) or in a follow-up phase.
  7. Persistent uncorrectable hypokalemia and hypomagnesemia at the time of enrollment.
  8. Symptomatic or untreated brain metastases.
  9. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
  10. Concurrent administration of other anti-neoplastic treatments.
  11. Individuals with an allergic constitution or known hypersensitivity to any component of the study medication.
  12. Patients with a propensity for gastrointestinal bleeding, including but not limited to:
  13. Active ulcers with fecal occult blood (++); 2) History of melena or hematemesis within the past 2 months; 3) For fecal occult blood (+) and the primary tumor site not surgically removed, a gastroscopy is required, and patients with visible active bleeding are ineligible.
  14. Active infections, including but not limited to tuberculosis. 14. History of immunodeficiency, including positive HIV testing, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  15. Severe cardiac conditions within the past 6 months, including but not limited to:
  16. Acute coronary syndrome;
  17. Clinically significant arrhythmias requiring medication or unable to discontinue medications that may prolong the QT interval during the study;
  18. Acute myocardial infarction;
  19. Heart failure;
  20. Any other cardiac condition deemed unsuitable for trial participation by the investigator.
  21. Pregnant or lactating women, or women of childbearing potential with a positive baseline pregnancy test.
  22. Serious comorbidities judged by the investigator to endanger patient safety or impede study completion, such as hypertension, severe diabetes, thyroid disorders, etc.
  23. Habitual alcohol consumption, smoking (≥5 cigarettes daily), and other detrimental lifestyle habits; heavy episodic drinking is defined as consuming approximately four or more drinks within 2 hours, where one drink is equivalent to 150 mL of wine, 350 mL of beer, or 50 mL of 80-proof spirits.
  24. History of definite neurological or psychiatric disorders, including epilepsy or dementia.

引自 ClinicalTrials.gov, NCT06684600, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06684600,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06684600